Robert M Knabb
Overview
Explore the profile of Robert M Knabb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knabb R, Wexler R
J Thromb Thrombolysis
. 2021 Aug;
52(2):403-407.
PMID: 34351559
Over the past few decades, drug discovery directed at the treatment and prevention of thromboembolic diseases has been challenged by the need to balance robust efficacy with improved safety relative...
2.
Perera V, Luettgen J, Wang Z, Frost C, Yones C, Russo C, et al.
Br J Clin Pharmacol
. 2018 Jan;
84(5):876-887.
PMID: 29346838
Aims: The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-962212, a first-in-class factor XIa inhibitor, in Japanese and non-Japanese healthy subjects....
3.
Lester P, Coleman D, Diaz J, Jackson T, Hawley A, Mathues A, et al.
Arterioscler Thromb Vasc Biol
. 2017 Feb;
37(5):942-948.
PMID: 28232327
Objective: Warfarin is the current standard for oral anticoagulation therapy in patients with mechanical heart valves, yet optimal therapy to maximize anticoagulation and minimize bleeding complications requires routine coagulation monitoring,...
4.
Orwat M, Qiao J, He K, Rendina A, Luettgen J, Rossi K, et al.
Bioorg Med Chem Lett
. 2014 Jun;
24(15):3341-5.
PMID: 24951330
In an effort to identify a potential back-up to apixaban (Eliquis®), we explored a series of diversified P4 moieties. Several analogs with substituted gem-dimethyl moieties replacing the terminal lactam of...
5.
Zhang X, Jiang W, Jacutin-Porte S, Glunz P, Zou Y, Cheng X, et al.
ACS Med Chem Lett
. 2014 Jun;
5(2):188-92.
PMID: 24900796
Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide...
6.
Priestley E, De Lucca I, Zhou J, Zhou J, Saiah E, Stanton R, et al.
Bioorg Med Chem Lett
. 2013 Mar;
23(8):2432-5.
PMID: 23478148
A 6-amidinotetrahydroquinoline screening hit was driven to a structurally novel, potent, and selective FVIIa inhibitor through a combination of library synthesis and rational design. An efficient gram-scale synthesis of the...
7.
Zhang X, Glunz P, Jiang W, Schmitt A, Newman M, Barbera F, et al.
Bioorg Med Chem Lett
. 2013 Feb;
23(6):1604-7.
PMID: 23416003
Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors. SAR demonstrated that the S2 and S3 pockets of FVIIa prefer to bind small, lipophilic groups. An...
8.
Pinto D, Qiao J, Knabb R
Expert Opin Ther Pat
. 2012 Jun;
22(6):645-61.
PMID: 22655676
Introduction: Factor Xa (FXa) is a critical enzyme in the coagulation cascade responsible for thrombin generation, the final enzyme that leads to fibrin clot formation. Significant success has recently been...
9.
A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors
Barrett Y, Wang Z, Knabb R
Clin Appl Thromb Hemost
. 2012 Apr;
19(5):522-8.
PMID: 22473028
Conventional prothrombin time (PT) assays have limited sensitivity and dynamic range in monitoring the anticoagulant activity of direct factor Xa inhibitors. Hence, new assays are needed. We modified a PT...
10.
Goldhaber S, Leizorovicz A, Kakkar A, Haas S, Merli G, Knabb R, et al.
N Engl J Med
. 2011 Nov;
365(23):2167-77.
PMID: 22077144
Background: The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe...